Good for ↑
The FDA has approved Moderna's mRNA-based influenza vaccine, reversing an earlier refusal to even review the application following public outcry. This marks a significant regulatory milestone for Moderna's pipeline beyond COVID.
Source: The New York Times ↗
An FDA approval is a hard Tier A catalyst that directly expands Moderna's commercial addressable market into the large seasonal flu vaccine space. The stock is likely to gap up and sustain momentum over the next days-to-weeks as analysts revise revenue estimates upward. This approval validates Moderna's mRNA platform for non-COVID indications, a key investor concern.
Market had largely discounted this approval given the FDA's initial refusal to review the application; sentiment was cautious and the stock likely underpriced the probability of approval.
Why that may be wrong
Because the FDA initially refused to review the application, the market likely assigned a low probability to approval; the actual approval triggers mechanical analyst estimate upgrades and institutional re-rating of Moderna's pipeline optionality that takes days-to-weeks to fully diffuse.
If Moderna's label comes with severe restrictions (e.g., narrow age indication, black-box warning) that limit commercial uptake, or if a competitor flu vaccine approval is announced simultaneously — observable via the FDA approval letter details or a competing press release within days.
MRNA has a history of fading post-approval pops as commercial execution disappoints; if Q3 guidance on flu vaccine manufacturing capacity is weak on the next earnings call, the stock could give back gains quickly.
When Moderna received its first COVID vaccine EUA in December 2020, MRNA surged ~20% in the two weeks following the announcement. More recently, BioNTech (BNTX) gained ~15% in the week after its mRNA RSV vaccine received FDA approval in May 2024, illustrating the market's consistent re-rating of mRNA platform companies on new approvals.
No comments yet.
Sign in to comment